Dr. Xu Che 车旭
Chief Physician
Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and minimally invasive surgery for pancreatic, hepatobiliary, liver metastasis, gastrointestinal, pancreatic neuroendocrine, and retroperitoneal tumors. Focuses on comprehensive immunotherapy and translational research.
Dr. Che holds MD and PhD degrees in Oncology from Peking Union Medical College. A visiting scholar at Johns Hopkins University School of Medicine in 2016, Dr. Che conducted research on immunotherapy for digestive tract tumors under Elizabeth Jaffee. Research interests include genetic variations and pancreatic cancer susceptibility.
Professional roles
- Member, International Hepato-Pancreato-Biliary Association (IHPBA)
- Member, Asia-Pacific Hepato-Pancreato-Biliary Association (A-PHPBA)
- Member, Hepatobiliary and Pancreatic Surgery Group, Expert Committee on Enhanced Recovery After Surgery, National Health Commission
- Secretary General, Pancreatic Disease Branch, China International Exchange and Promotive Association for Medical and Health Care
Name order: in Chinese the family name comes first (Che Xu). Papers usually list the name as Xu Che or Che X.
Selected publications
54 papers on PubMed matched by name and affiliation; 32 as first or senior author since 2016. Most recent first- or senior-author papers:
- Eur J Cancer Prev, 2026 (senior author): Association between female reproductive factors and new-onset pancreatic cancer risk: a prospective cohort study. PubMed 40889131
- Discov Oncol, 2025 (senior author): Surgical intervention strategies for tumor microenvironment (TME) associated therapeutic resistance. PubMed 41342961
- BMC Cancer, 2025 (senior author): Preoperative circulating tumor cells indicate microvascular invasion and dynamical detection indicate the early recurrence of hepatocellular carcinoma. PubMed 40596968
- Front Oncol, 2024 (senior author): Sorafenib combined with tarexib for first-line treatment of unresectable hepatocellular carcinoma and its predictive role and correlation with PD-L1 CTCs. PubMed 39687892
- Front Oncol, 2024 (senior author): Laparoscopic liver resection versus radiofrequency ablation for hepatocellular carcinoma within Milan criteria: a meta-analysis and systematic review. PubMed 39629003
- Crit Rev Oncol Hematol, 2024 (senior author): Spatial transcriptomics in pancreatic cancer: Advances, prospects and challenges. PubMed 38942220
- J Gastroenterol Hepatol, 2024 (senior author): Postoperative adjuvant chemotherapy is important for improving long-term survival in patients with colorectal cancer liver metastases undergoing simultaneous resection. PubMed 38323685
- Front Oncol, 2023 (senior author): Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review. PubMed 36776344
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion